Skip to content
Riskpilot
← Back to search
Sign in
Get full access
JVV-Pharma Oy
OY
Active
Y-tunnus 3087608-9
Puntarikatu 3, 20780
Kaarina
Retail sale of medical and orthopaedic goods
· NACE 4774
Est. 2019
— employees
Watchlist
Share
Finland
/
Companies
/
Retail sale of medical and orthopaedic goods
/
JVV-Pharma Oy
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
EUR millions
0M
0M
1M
1M
1M
1M
2021
1M
2022
1M
2023
1M
2024
1M
2025
EBITDA
EUR millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
0M
2025
Income statement
EUR thousands
Item
2021
2022
2023
2024
2025
Revenue
603
1 201
1 214
1 215
1 225
Staff expenses
—
—
−0
−0
−0
EBITDA
170
351
358
374
407
Depreciation & amort.
—
—
−33
−32
−18
EBIT
170
351
325
342
389
Net financials
0
0
2
2
0
Profit before tax
170
351
326
344
390
Tax
34
70
65
69
78
Net profit
136
281
261
275
312
Balance sheet
EUR thousands
Item
2021
2022
2023
2024
2025
Total assets
296
583
799
1 000
1 242
Equity
269
528
747
962
1 197
Long-term debt
—
—
0
0
0
Short-term debt
27
54
52
38
46
Total debt
27
54
52
38
46
Financial ratios
5-year trend
EBITDA margin
33.2%
This company
15.8%
Market median
+110% vs market
2021
2025
Equity ratio
96.3%
This company
38.2%
Market median
+152% vs market
2021
2025
Return on equity
26.0%
This company
18.4%
Market median
+41% vs market
2021
2025
Net profit margin
25.4%
This company
8.1%
Market median
+214% vs market
2021
2025
Asset turnover
0.99×
This company
1.12×
Market median
+12% vs market
2021
2025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
View
PDF
More on JVV-Pharma Oy
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
